报告预览

有您的支持，我们的分析师会做的更好 ！

当前，全球病毒变异迭代加速，公共卫生防控常态化需求持续凸显，叠加中国生物医药技术创新升级与政策精准赋能，病毒防治产业正迎来新一轮发展机遇与调整周期。全球领先的新经济产业第三方数据挖掘和分析机构iiMedia Research（艾媒咨询）最新发布的《2025年中国病毒防治产业发展状况及重点企业大数据监测报告》显示，2025年病毒防治产业集中度持续提升，营收前三名企业合计贡献TOP10整体营收的42.13%，研发投入累计投入达16.59亿元，头部引领效应凸显。细分领域中，以岭药业依托中药防治优势实现扭亏为盈，前三季度归母净利润实现10亿元，毛利率维持60%以上；华大基因深耕精准医学检测细分领域，前三季度营收规模超25亿元，市净率达2.29倍，展现出细分赛道的发展韧性。艾媒咨询分析师认为，2025年病毒防治产业处于调整转型期，研发创新、产品迭代及市场布局优化成为企业突破发展瓶颈、提升核心竞争力的关键，同时也将逐步筑牢公共卫生安全保障的产业根基，推动构建人类卫生健康共同体。
　　At present, the global iteration of virus variants is accelerating, and the demand for the normalization of public health prevention and control remains prominent. Coupled with the innovation and upgrading of China's biopharmaceutical technology and precise policy support, the virus prevention and control industry is ushering in a new round of development opportunities and adjustment cycle. According to the 2025 Report on the Development Status of China's Virus Prevention and Control Industry and Big Data Monitoring of Key Enterprises newly released by iiMedia Research, a world-leading third-party institution for data mining and analysis of the new economy industry, the concentration of the virus prevention and control industry continued to rise in 2025. The top three enterprises in terms of revenue contributed 42.13% of the total revenue of the top 10 enterprises combined, with a cumulative R&D investment of 1.659 billion yuan, highlighting the leading effect of head enterprises.
　　In the segmented sectors, Yiling Pharmaceutical turned losses into profits by virtue of its advantages in traditional Chinese medicine (TCM) prevention and control, achieving a net profit attributable to shareholders of listed companies of 1 billion yuan in the first three quarters with a gross profit margin maintained above 60%. BGI Genomics has deepened its layout in the segmented field of precision medical testing, recording a revenue scale of over 2.5 billion yuan in the first three quarters and a price-to-book ratio of 2.29 times, demonstrating the development resilience of the segmented track.
　　Analysts from iiMedia Research hold that the virus prevention and control industry is in a period of adjustment and transformation in 2025. R&D innovation, product iteration and optimization of market layout have become the key for enterprises to break through development bottlenecks and enhance core competitiveness. Meanwhile, this will gradually consolidate the industrial foundation for public health security and boost the building of a global community of health for all.